构橼酸烟胺乙酯 | 1641-74-3

• 物质功能分类: 化学试剂 - 有机试剂
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: 构橼酸烟胺乙酯
• 中文别名: 枸橼酸烟胺乙酯；[2-(3-吡啶甲酰氧)乙基]-二乙基胺柠檬酸盐
• 英文名称: diethyl[2-(3-pyridiniocarbonyloxy)ethyl]ammonium hydrogen citrate
• 英文别名: nicametate citrate；2-(diethylamino)ethyl pyridine-3-carboxylate;2-hydroxypropane-1,2,3-tricarboxylic acid
• CAS: 1641-74-3
• 化学式: C₆H₈O₇*C₁₂H₁₈N₂O₂
• 分子量: 414.412
• InChiKey: IABBAGAOMDWOCW-UHFFFAOYSA-N

物化性质

• 熔点：
  123 °C

计算性质

• 辛醇/水分配系数(LogP)：
  0.33
• 重原子数：
  29
• 可旋转键数：
  12
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  175
• 氢给体数：
  4
• 氢受体数：
  11

安全信息

• 海关编码：
  2933399090
• 储存条件：
  室温且干燥

制备方法与用途

烟胺乙酯的稳定非吸湿性酸加成盐的制备方法是，在化学计量或略微过量的烟胺乙酯中，优选溶解于有机溶剂中的脂族羟基羧酸溶液。所得产物在相同的溶剂中结晶或形成酸加成盐，并借助沉淀作用分离，其中酸加成盐在溶剂中的溶解度不超过微溶水平；而所使用的酸和碱则是可溶的。已知通过使用无机酸如盐酸或硫酸处理烟胺乙酯碱来制备此类酸加成盐，例如枸橼酸烟胺乙酯。

文献信息

• Percutaneous absorption-type pharmaceutical preparation
  申请人：Inosaka Keigo

  公开号：US20060275354A1

  公开（公告）日：2006-12-07

  A stable percutaneous absorption-type pharmaceutical preparation for percutaneous administration of drugs except for selegiline and selegiline hydrochloride, which does not suffer a decrease in the cohesive force of the adhesive layer therein even in the presence of sweat components due to perspiration during wear and which is free from cohesive failure and resultant adhesive remaining when stripped off. A percutaneous absorption-type pharmaceutical preparation which comprises: a support; and an adhesive layer containing an adhesive, a metal chloride and a percutaneously-absorptive drug except for selegiline and selegiline hydrochloride, wherein the adhesive layer is subjected to a crosslinking treatment.

  一种稳定的经皮吸收型药物制剂，用于除去赛洛吉林和赛洛吉林盐酸盐以外的药物的经皮给药，即使在穿戴过程中由于出汗而存在汗液成分时也不会减少粘合层的粘合力，并且在剥离时不会出现内聚力失效和残留粘合剂。一种经皮吸收型药物制剂，包括：一种支撑物；和一个含有粘合剂、金属氯化物和除赛洛吉林和赛洛吉林盐酸盐之外的经皮吸收药物的粘合层，其中粘合层经过交联处理。
• MANUFACTURING METHOD AND APPARATUS OF ULTRAFINE PARTICLES HAVING UNIFORM PARTICLE SIZE DISTRIBUTION
  申请人：Hwang Sung Joo

  公开号：US20110200678A1

  公开（公告）日：2011-08-18

  The present invention relates to a novel technology for forming fine particles with a size of 0.02˜3 microns from a solid that can be dissolved in a liquid solvent and is not decomposed by heat. The particle preparation technology according to the present invention may be applicable to the fields of food, cosmetics, biopolymer, polymer compositions, and pharmaceuticals.

  本发明涉及一种新型技术，用于从可溶于液体溶剂且不会被热分解的固体中形成粒径为0.02〜3微米的细小颗粒。本发明的颗粒制备技术可适用于食品、化妆品、生物聚合物、聚合物组合物和制药等领域。
• AQUEOUS COMPOSITION
  申请人：Yaginuma Yoshihito

  公开号：US20100172978A1

  公开（公告）日：2010-07-08

  Disclosed is an aqueous composition containing (a) an ethyl acrylate/methyl methacrylate copolymer or a plasticized vinyl accetate polymer, (b) an ethyl cellulose, (c) a water soluble additive for pharmaceutical products, (d) titanium oxide and (c) water. The solid content mass ratio among the components (a), (b), (c) and (d), namely a:b:c:d is 100:(5-50):(1-50):(0.5-10), and the solid content concentration in the aqueous composition is 0.5-40% by mass.

  本发明涉及一种水性组合物，包含(a)乙基丙烯酸酯/甲基丙烯酸甲酯共聚物或增塑的乙烯醋酸乙烯酯聚合物，(b)乙基纤维素，(c)水溶性药品添加剂，(d)二氧化钛和(c)水。组分(a)、(b)、(c)和(d)的固体含量质量比，即a:b:c:d为100:(5-50):(1-50):(0.5-10)，水性组合物中的固体含量浓度为0.5-40%。
• Sustained release preparation
  申请人：TEIJIN LIMITED

  公开号：EP0187703A2

  公开（公告）日：1986-07-16

  A sustained release preparation comprising: (a) chitin, chitosan, or a mixture thereof (b) anionic polymer compounds such as those having a carboxyl group, a sulfonic acid group, or a group capable of providing the same, and (c) pharmaceutically active agents. This sustained release preparation can provide the desired sustained-release or dissolution of the pharmaceutically active agents in human organs irrespective of the acidity (i.e., pH conditions) therein.

  一种缓释制剂，包括：(a) 甲壳素、壳聚糖或它们的混合物；(b) 阴离子聚合物化合物，如具有羧基、磺酸基或能提供相同羧基、磺酸基的化合物；(c) 药物活性剂。 这种缓释制剂能在人体器官中提供所需的药物活性剂的缓释或溶解，而不受其中酸度（即 pH 值条件）的影响。
• Novel plaster structure for iontophoresis
  申请人：YAMANOUCHI PHARMACEUTICAL CO. LTD.

  公开号：EP0269246A2

  公开（公告）日：1988-06-01

  A plaster structure for iontophoresis comprising an electrode layer (4) and a medicament-containing layer (1), wherein a water supplying layer - composed of a water-containing lamina (2) and/or a water-containing self-adhesive lamina (3) - is formed between the electrode layer (4) and the medicament-containing layer (1), and further a sealing cover (5) is formed at the outside of the electrode layer (4).

  一种用于离子透入疗法的膏药结构，包括电极层（4）和含药层（1），其中在电极层（4）和含药层（1）之间形成一个由含水薄层（2）和/或含水自粘薄层（3）组成的供水层，并在电极层（4）外侧形成一个密封盖（5）。